Immuno AG
Austrian pharmaceutical company founded in 1960 and acquired by Baxter in 1996
Immuno AG was a major pharmaceutical company founded in 1960 by Dr. Otto Schwarz & Dr. Hans Eibl. Its headquarters are located in Vienna, Austria.
In 1996, the company was acquired by Baxter for $715 million.
Business
Immuno-manufactured blood products including factor VIII and factor IX such as Kryobulin and Krobulin TIM.
Lawsuits
In 1983, Immuno sued Dr. Shirley McGreal and several others claiming $4 million in damages for an article claiming that the company planned to use captured chimpanzees for hepatitis research in Sierra Leone.
In 1986, two civil lawsuits were brought against Immuno by the Association Against Animal Experimentation in regard to the treatment of chimpanzees.
The plant in Krems, which was set up in 2002 but never went into operation, was subjected to an examination of its further usability in the course of 2013. The partial expansion was announced in autumn of 2013: "In the first expansion stage, a production line is initially planned, and there is sufficient space for possible future expansions.
Begin with the source’s own compact description: “Immuno AG” is austrian pharmaceutical company founded in 1960 and acquired by Baxter in 1996. The dossier treats that line as a proposition to test through Immuno, Austrian and pharmaceutical, not as a finished interpretation.
Why this record matters
The phrase “austrian pharmaceutical company founded in 1960 and acquired by Baxter in 1996” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Chronology, provenance and viewpoint should be read together before a broad social or political interpretation is accepted. The source revision retrieved here is dated Jan 15, 2025. The linked authority identifier is Q812048. None of the 1 selected statements returned an explicit reference. The first chronological checks are 1960, 1996, 1983 and 1986.
Later summaries often reconcile disputed chronology or motive more neatly than the contemporary record permits. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Immuno AG”, its source revision and the description used here.
- Expand the search: follow Immuno AG primary sources, Immuno AG archive and Immuno research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Immuno AG”?
- What chronology connects this entry to wider political or social change?
- Who created the surviving record, and for what administrative purpose?
Search terms from this dossier
This entry incorporates text from “Immuno AG” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.